Effects of lamivudine on the function of dendritic cells derived from patients with chronic hepatitis B virus infection

Table 1 The expression of DCs disposed by LAM (mean ± SD, n = 15)

	CD83	CD80	CD1α	HLA-DR
DC	12.83 ± 2.12	35.82 ± 2.41	33.57 ± 3.14	52.80 ± 2.51
DC + LAM 0.125 mmol/L	13.40 ± 2.16	37.73 ± 3.24	40.26 ± 2.09	53.70 ± 3.27
DC + LAM 0.25 mmol/L	18.30 ± 3.15	41.13 ± 3.61	53.10 ± 2.79	67.83 ± 4.15
DC + LAM 0.5 mmol/L	20.24 ± 2.51a	41.73 ± 4.18	54.10 ± 4.21a	74.50 ± 5.16a
DC + LAM 1 mmol/L	12.81 ± 2.31	25.66 ± 3.05	16.55 ± 1.95	42.11 ± 3.91
DC + LAM 2 mmol/L	11.92 ± 1.28	24.67 ± 2.62	16.54 ± 1.76	41.01 ± 3.52

DC: Dendritic cell; LAM: Lamivudine.

^aP <0.05 vs DC + LAM 0 mmol/L group.

Table 2 The stimulatory ability of DCs treated with LAM in allogeneic mixed leukocyte reactions (mean ± SD, n = 15)

		Control group			LAM (mmol/L)
		0.125	0.25	0.5	1	2
SI	1.24 ± 0.51	1.31 ± 0.56	1.54 ± 0.45	1.87 ± 0.6a	0.9 ± 0.39	0.63 ± 0.3a

SI: Stimulator index; DC: Dendritic cell; LAM: Lamivudine.

^aP < 0.05 vs control group.